Basilea Pharmaceutica AG
BPMUF
$71.00
-$0.60-0.84%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.93% | 24.59% | 51.70% | 39.13% | 32.76% |
| Total Other Revenue | 196.77% | 230.18% | 313.69% | 184.45% | 91.25% |
| Total Revenue | 18.49% | 35.94% | 62.20% | 45.44% | 35.48% |
| Cost of Revenue | 33.69% | 17.80% | 3.77% | 5.47% | 12.34% |
| Gross Profit | -0.45% | 73.02% | 365.71% | 165.38% | 82.19% |
| SG&A Expenses | 19.60% | 13.98% | 9.13% | 3.07% | 1.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.72% | 17.02% | 4.83% | 4.96% | 9.94% |
| Operating Income | -10.46% | 138.66% | 1,229.08% | 857.45% | 200.80% |
| Income Before Tax | -19.29% | 158.70% | 621.25% | 3,397.36% | 542.33% |
| Income Tax Expenses | 134.39% | 118.39% | 97.48% | -29.58% | -188,415.38% |
| Earnings from Continuing Operations | -44.74% | 49.64% | 9,803.52% | 1,488.24% | 725.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.74% | 49.64% | 9,803.52% | 1,488.24% | 725.50% |
| EBIT | -10.46% | 138.66% | 1,229.08% | 857.45% | 200.80% |
| EBITDA | -9.55% | 128.77% | 1,834.99% | 656.99% | 182.46% |
| EPS Basic | -45.44% | 48.82% | 8,633.17% | 1,487.28% | 714.17% |
| Normalized Basic EPS | -20.28% | 157.59% | 614.45% | 3,384.33% | 533.13% |
| EPS Diluted | -42.87% | 56.04% | 2,366.40% | 5,604.67% | 1,249.21% |
| Normalized Diluted EPS | -18.30% | 176.66% | 528.90% | 1,379.84% | 861.09% |
| Average Basic Shares Outstanding | 1.35% | 1.24% | 1.12% | 0.81% | 0.71% |
| Average Diluted Shares Outstanding | 0.52% | 4.82% | 9.44% | 5.56% | 5.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |